Should GLP-1 agonists be considered an alternative or adjunct to pediatric metabolic and bariatric surgery? more questions than answers
- 28 October 2024
- journal article
- editorial
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (2) , 117-120
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to PrescribingCurrent Obesity Reports, 2024
- Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic ReviewObesity Surgery, 2024
- Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in AdolescentsJAMA Network Open, 2023
- Use of Metabolic and Bariatric Surgery Among US YouthJAMA Pediatrics, 2023
- ASMBS pediatric metabolic and bariatric surgery guidelines, 2018Surgery for Obesity and Related Diseases, 2018
- Differences in Obesity Prevalence by Demographics and Urbanization in US Children and Adolescents, 2013-2016JAMA, 2018
- Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysisThe Lancet Diabetes & Endocrinology, 2017
- Access to care for adolescents seeking weight loss surgeryObesity, 2014
- To Cut or Not to Cut: Physicians’ Perspectives on Referring Adolescents for Bariatric SurgeryObesity Surgery, 2010
- Cardiovascular Risk Factors and Excess Adiposity Among Overweight Children and Adolescents: The Bogalusa Heart StudyThe Journal of Pediatrics, 2007